KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study

S. Ferrero, D. Rossi, A. Rinaldi, A. Bruscaggin, V. Spina, C.W. Eskelund, A. Evangelista, R. Moia, I. Kwee, C. Dahl, A. Di Rocco, V. Stefoni, F. Diop, C. Favini, P. Ghione, A.M. Mahmoud, M. Schipani, A. Kolstad, D. Barbero, D. NoveroM. Paulli, A. Zamò, M. Jerkeman, M.G. Da Silva, A. Santoro, A. Molinari, A. Ferreri, K. Grønbæk, A. Piccin, S. Cortelazzo, F. Bertoni, M. Ladetto, G. Gaidano

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study'. Together they form a unique fingerprint.

Medicine & Life Sciences